Reduced survival in patients whose tumors have ATM and TP53 mutations, compared with patients with wild-type ATM and TP53 genes. (A) Overall survival (OS) in patients with CLL with ATM or TP53 mutations was reduced compared with patients with CLL with ATM/TP53 wild-type mutations, and these differences were significant (P < .001). (B) Treatment-free survival (TFS) in patients with ATM and TP53 mutations was reduced compared with patients with ATM/TP53 wild-type mutations, and these differences were also significant (P < .001).